Compare · BSX vs PDEX
BSX vs PDEX
Side-by-side comparison of Boston Scientific Corporation (BSX) and Pro-Dex Inc. (PDEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and PDEX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $62.46B, about 325.9x PDEX ($191.7M).
- Over the past year, BSX is down 58.7% and PDEX is up 67.2% - PDEX leads by 125.9 points.
- PDEX has been more active in the news (6 items in the past 4 weeks vs 4 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 0 for PDEX).
- Company
- Boston Scientific Corporation
- Pro-Dex Inc.
- Price
- -
- -
- Market cap
- $62.46B
- $191.7M
- 1M return
- -15.83%
- -10.83%
- 1Y return
- -58.70%
- +67.17%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 6
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Pro-Dex Inc.
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Latest BSX
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
Latest PDEX
- Chief Executive Officer Van Kirk Richard Lee Jr sold $1,165,290 worth of shares (19,235 units at $60.58) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,993 units (SEC Form 4)
- Chief Financial Officer Charlton Alisha sold $140,983 worth of shares (2,300 units at $61.30), decreasing direct ownership by 10% to 21,870 units (SEC Form 4)
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Fourth Quarter and Full-Year Results
- Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Domingo Angelita Rebamontan was granted 19 shares, increasing direct ownership by 0.10% to 18,798 units (SEC Form 4)
- Director Domingo Angelita Rebamontan sold $47,146 worth of shares (998 units at $47.24), decreasing direct ownership by 5% to 18,779 units (SEC Form 4)
- Chief Financial Officer Charlton Alisha was granted 10,800 shares and covered exercise/tax liability with 3,897 shares, increasing direct ownership by 40% to 24,170 units (SEC Form 4) (tax liability)
- Chief Executive Officer Van Kirk Richard Lee Jr was granted 14,800 shares and covered exercise/tax liability with 5,279 shares, increasing direct ownership by 11% to 99,228 units (SEC Form 4) to cover withholding tax